Skip to main content
SpringerLink
Log in

Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Background

Induction chemotherapy with docetaxel-cisplatin and 5-fluorouracil (DCF) for locally advanced head and neck cancers (HNC) is associated with a high risk of severe neutropenia or febrile neutropenia (FN). We conducted a retrospective study to evaluate the efficacy and safety of administering granulocyte colony-stimulating factor (G-CSF) on day 3 (D3) during chemotherapy (early G-CSF stimulation) versus after the end of chemotherapy, as per current guidelines (i.e., after the end of 5-FU perfusion; D7), and its impact on patient outcomes.

Patients and methods

Patients ≥19 years old, with advanced HNC who received DCF induction chemotherapy (D and P 75 mg per meter squared (mg/m2) on day 1 and 5-FU 750 mg/m2/day from D1 to D5), were included in the analysis.

Results

Data of 70 patients were analyzed from 01 January 2003 to 01 December 2010. Mean age was 56 years (range 45 to 77 years). Thirty-six patients (51.4 %) received pegfilgrastim on D7, and 28 (40 %) started G-CSF prophylaxis during chemotherapy; 12 (17.1 %) had daily filgrastim and 16 (22.9 %) pegfilgrastim on D3. Overall response rate (ORR) was 89.6 % (three early deaths due to infectious complications; 4.3 %). The 3-year overall survival (OS) rate was 72.8 %. FN rate was 14.3 % and chemotherapy delay was 12.9 %. In the D7 G-CSF arm, incidence of grade 3–4 neutropenia (p = 0.023), FN (p = 0.029), and cycle delays (p = 0.006) was statistically higher than the “early” G-CSF arm. A decrease of OS was observed at 2 years (from 85.1 to 63.5 %) of chemotherapy discontinuation or FN (p = 0.0348).

Discussion

Early administration of G-CSF is safe and seems to be more effective than D7. Future prospective trials are required to confirm our results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sturgis EM (2011) The International Head and Neck Cancer Epidemiology consortium. Head Neck 33(1):141

    Article  PubMed  Google Scholar 

  2. Zorat PL, Paccagnella A, Cavaniglia G et al (2004) Randomized phase III trial of neoadjuvant chemotherapy in head and neck: 10 year follow up. J Natl Cancer Inst 94:1714–1717

    Article  Google Scholar 

  3. Lorch JH, Posner MR, Wirth LJ et al (2008) Induction chemotherapy in locally advanced head and neck cancer. A new standard of care? Hematol Oncol Clin N Am 22:115–163

    Article  Google Scholar 

  4. Pointreau Y, Garaud P, Chapet S et al (2009) Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101:498–506

    Article  CAS  PubMed  Google Scholar 

  5. Paccagnella A, Ghi MG, Loreggian L et al (2010) Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 21:1515–1522

    Article  CAS  PubMed  Google Scholar 

  6. Hitt R, Grau JJ, Lopez-Pousa A et al (2009) Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU followed by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 27 (15 suppl abstr 6009)

  7. Bonnin N, Ceruse P, Bachelot T, et al (2008) Efficacy of neoadjuvant TPF (nTPF; docetaxel, T; cisplatin, P; 5FU) in nonselected patients (pts) with head and neck cancer and subsequent radiotherapy (RT) combined with chemotherapy (CT) or cetuximab (Cx). J Clin Oncol 26 (suppl2 0, abstr 6074).

  8. Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705–1715

    Article  CAS  PubMed  Google Scholar 

  9. Vermorken JB, Remenar E, van Herpen C et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695–1704

    Article  CAS  PubMed  Google Scholar 

  10. Paccagnella A, Mastromauro C, D’Amanzo P, Ghi M (2010) G. Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future? Oncologist 15:8–12

    Article  CAS  PubMed  Google Scholar 

  11. Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205

    Article  CAS  PubMed  Google Scholar 

  12. Crawford J, Althaus B, Armitage J et al (2007) National Comprehensive Cancer Network (NCCN). Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw 5:188–202

    CAS  Google Scholar 

  13. Holmes FA, O’Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or III/IV breast cancer. J Clin Oncol 20:727–731

    Article  CAS  PubMed  Google Scholar 

  14. Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36–46

    Article  CAS  PubMed  Google Scholar 

  15. Webb A, Cunningham D, Scarffe JH et al (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261–267

    Article  CAS  PubMed  Google Scholar 

  16. Hoffman PS (2005) Administration of pegfilgrastim on the same-day or next-day of chemotherapy. J Clin Oncol 23 (Suppl 16, Abstr 8137).

  17. Belani CP, RamalingamS, Al-janadi A, et al (2006) A randomized double-blind phase 2 study to evaluate same-day vs. next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC. J Clin Oncol 24 (Suppl 18, Abstr 7110).

  18. Lokich J (2005) Same-day pegfilgrastim and chemotherapy. Cancer Investig 23:573–576

    Article  CAS  Google Scholar 

  19. Shuman I, Lambrou N, Robson K et al (2009) Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. J Support Oncol 7:225–228

    Google Scholar 

  20. Matthews KS, Shipman KA et al (2009) The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol 112(3):601–604

    Article  PubMed  Google Scholar 

  21. Saven A, Schwartzberg L, Kaywin P, et al (2006) Randomized double-blind, phase 2 study evaluating same-day vs. next-day administration of pegfilgrastim with R-CHOP in non-Hodgkin’s lymphoma patients. J Clin Oncol 24 (suppl 18, Abstr 7570).

  22. Lokich JJ (2006) Same-day pegfilgrastim and CHOP chemotherapy for non Hodgkin lymphoma. Am J Clin Oncol 29:361–363

    Article  CAS  PubMed  Google Scholar 

  23. Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8–32

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflicts of interest.

Author information

Authors and Affiliations

  1. Oncopharmacology—Pharmacogenetics Department, Institut de Cancérologie de l’Ouest Nantes-Angers, 2 rue Moll, 49033, Angers Cedex, France

    B. Linot, P. Augereau & O. Capitain

  2. Head and Neck Surgery Department, Centre Hospitalo-Universitaire, Angers, France

    R. Breheret & L. Laccourreye

Authors
  1. B. Linot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Augereau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Breheret
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Laccourreye
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O. Capitain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Linot.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Linot, B., Augereau, P., Breheret, R. et al. Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study. Support Care Cancer 22, 2831–2837 (2014). https://doi.org/10.1007/s00520-014-2270-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-014-2270-8

Keywords

Search

Navigation